Study of immunotherapy, chemotherapy, and cryoablation for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy (sintilimab), chemotherapy, and a freezing treatment called cryoablation for people with advanced non-squamous non-small cell lung cancer that has not been treated before. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-squamous non-small cell lung cancer that is at stage IIIB, IIIC, or IV, and it has not been treated with systemic therapy (like chemotherapy or immunotherapy) before.
- The main tumor in your lung is less than 5 cm across, not next to major blood vessels, and in a spot where a needle can safely reach it for freezing treatment.
- Your cancer does not have certain gene changes (EGFR or ALK) that would guide treatment to targeted pills.
- You are in good enough health to be up and about (ECOG score 0 or 1), and your organs are working well (like having enough white blood cells and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (serplulimab) to a procedure called cryoablation (freezing tumors) works better than cryoablation alone for people with early-stage non-small cell lung cancer that has not spread. It is for patients who cannot or choose not to have surgery or radiation.
This trial uses a freezing technique (cryoablation) through a bronchoscope to shrink tumors blocking the main airways. It is combined with standard chemotherapy and immunotherapy (pembrolizumab) to treat advanced lung cancer that hasn't been treated before.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.